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Summary
Background Inclusive universal health coverage requires access to quality health care without financial barriers. 
Receipt of palliative care after advanced cancer diagnosis might reduce household poverty, but evidence from 
low-income and middle-income settings is sparse.
Methods In this prospective study, the primary objective was to investigate total household costs of cancer-related 
health care after a diagnosis of advanced cancer, with and without the receipt of palliative care. Households comprising 
patients and their unpaid family caregiver were recruited into a cohort study at Queen Elizabeth Central Hospital in 
Malawi, between Jan 16 and July 31, 2019. Costs of cancer-related health-care use (including palliative care) and health-
related quality-of-life were recorded over 6 months. Regression analysis explored associations between receipt of 
palliative care and total household costs on health care as a proportion of household income. Catastrophic costs, 
defined as 20% or more of total household income, sale of assets and loans taken out (dissaving), and their association 
with palliative care were computed.
Findings We recruited 150 households. At 6 months, data from 89 (59%) of 150 households were available, comprising 
89 patients (median age 50 years, 79% female) and 64 caregivers (median age 40 years, 73% female). Patients in 
55 (37%) of the 150 households died and six (4%) were lost to follow-up. 19 (21%) of 89 households received palliative 
care. Catastrophic costs were experienced by nine (47%) of 19 households who received palliative care versus 48 (69%) 
of 70 households who did not (relative risk 0·69, 95% CI 0·42 to 1·14, p=0·109). Palliative care was associated with 
substantially reduced dissaving (median US$11, IQR 0 to 30 vs $34, 14 to 75; p=0·005). The mean difference in total 
household costs on cancer-related health care with receipt of palliative care was –36% (95% CI –94 to 594; p=0·707).
Interpretation Vulnerable households in low-income countries are subject to catastrophic health-related costs 
following a diagnosis of advanced cancer. Palliative care might result in reduced dissaving in these households. 
Further consideration of the economic benefits of palliative care is justified.
Funding Wellcome Trust; National Institute for Health Research; and EMMS International. 
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Globally, 18 million new cases of cancer were recorded 
in 2018 and 9·5 million people with cancer died.1 By 2030, 
a 70% increase in annual cancer cases and deaths is 
predicted in Africa.2 Cancer diagnosis has profound 
consequences for households in low-income and middle-
income countries. A recent study of more than 
9000 patients with cancer in southeast Asia reported that 
75% of patients had either died or faced financial 
catastrophe 12 months from diagnosis.3 Studies from 
some comparative settings in Uganda and South Africa 
report high mortality, catastrophic social and financial 
consequences, as well as accompanying psychological 
(anxiety) and spiritual (transcendent) morbidity.4 For the 
few people who access potentially curative therapy, loss 
to follow-up rates reported in Malawi are high.5
Palliative care is part of the continuum of care needed 
to tackle the heavy burden of serious health-related 
suffering experienced by patients with chronic 
non-communicable diseases, although it is widely 
unavailable and has not yet been the subject of extensive 
research in low-income settings in countries in Africa.6,7 
Positive health and economic benefits of palliative care 
have been reported in systematic reviews, although there 
are inherent challenges in estimating cost-effectiveness 
in populations with life-limiting illness.8,9 Much of the 
current literature is from high-income settings and 
describes the effect of palliative care on cost savings at a 
health system level. Current approaches have largely 
failed to capture relevant data from low-income and 
middle-income countries, where cost savings at 
household level are acutely important for patients and 
families, and to inform policy makers.10,11
A study in South Africa reported that palliative care 
reduced repeat admissions to hospital.12 Patients and 
families affected by advanced cancer in Malawi valued 
palliative care for pain and symptom control, facilitating 
reintegration into society, enabling patients to return to 
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household livelihood activities or paid work, which 
benefitted wellbeing.13 Timely and compassionate advice 
for families could reduce or stop the urge to find a cure by 
so-called doctor shopping.14 Hitherto, there are no data 
from countries in Africa reporting household level costs of 
health care in settings of advanced cancer, and the potential 
for palliative care to prevent or reduce financial catastrophe.
By use of a societal perspective, we aimed to investigate 
whether total household costs on health care are 
associated with receipt of palliative care in Malawi after a 
diagnosis of advanced cancer.
Methods 
Study design 
We undertook a prospective observational study among 
households in which a patient had received a new 
diagnosis (between January and July 2019) of advanced 
cancer at Queen Elizabeth Central Hospital, Blantyre, 
Malawi between Jan 16 and July 31, 2019. Given the 
relatively limited survival times anticipated for patients 
affected by advanced cancer, data were gathered on 
health-care costs related to cancer illness as well as 
health-related quality of life (HRQoL) between diagnosis 
and 6 months following diagnosis.
Queen Elizabeth Central Hospital is one of four tertiary 
referral teaching hospitals in Malawi. Palliative care 
services at the hospital fulfil criteria for African Palliative 
Care Association Level 3—ie, specialist services, 
including availability of morphine at site and in the 
home, and degree-level training represented in the 
team.15 At the time of the study, adult palliative care 
services in this hospital comprised two clinicians 
(one doctor and one clinical officer), four nurses, a part 
time chaplain or driver, and a cleaner. New patients were 
assessed using a form to identify physical, psychological, 
social, and spiritual needs and concerns of patients and 
caregivers. Outpatient and home visiting services took 
place. Referrals to palliative care were made at the 
discretion of attending clinicians from wards and 
outpatient clinics. Common reasons for referral included 
pain and symptom relief, counselling of patients and 
families on disease understanding, and social needs 
such as nutritional support. Palliative care services were 
delivered concurrently with other specialist services; 
palliative care could be started (or stopped) at any stage 
of the patient’s illness journey as was appropriate to 
their needs.
Basic costs of health services at the hospital, including 
oncology and palliative care, were met by government 
funding through the Ministry of Health. Following 
registration at minimal cost, services were provided free 
of charge to the patient. Supplementary donor funding for 
palliative care supports some salaries of health workers, 
medications, nutritional support, and transportation for 
home visits.
This study has undergone ethical review by, and 
received approval from, the College of Medicine Research 
Ethics Committee in Blantyre, Malawi, and the Liverpool 
Research in context
Evidence before this study
We searched MEDLINE/PubMed and CINAHL/EBSCO, Web of 
Science, EconLit, Ovid MEDLINE, Global Health, and African 
Journals Online to identify studies reporting on household 
costing in low-middle-income and middle-income countries 
relevant to a palliative care patient population. Reference lists 
from identified studies were searched to identify further 
literature. Searches were limited to articles published between 
Jan 1, 1992 and Dec 31, 2020 and the terms used were: Palliative 
care: MH (“Palliative Care”) OR MH (“Palliative Medicine”) OR 
end of life” OR “terminal illness*” OR “terminal care” OR “end-
of-life”; Cost of illness: MH (“Cost of Illness”) “economic burden” 
OR “household burden” OR “out of pocket” OR “out-of-pocket” 
OR “financial burden” OR “financial strain” OR “cost of care” OR 
“cost of illness” OR “direct cost*” OR “indirect cost*” OR “illness 
cost*” OR “financial stress” OR “catastrophic expenditure” OR 
“poverty reduction”; Context: LMIC MH (“Developing 
Countries”) ”developing countr*” OR LMIC OR “low resource” OR 
“low income” OR “low to middle income” OR “low-to-middle 
income” OR “least developed countr*” OR “underdeveloped 
countr*” OR “poor countr*” OR “underdeveloped nation*” OR 
“least developed nation*” OR “low and middle-income 
countries”. 30 articles were identified. Studies report high levels 
of catastrophic expenditure following a diagnosis of cancer in 
low-income and middle-income countries. Palliative care was 
mentioned in four papers (India, China, Colombia, global) but 
no published studies explored the impact of palliative care on 
household expenditure on health care or catastrophic 
expenditure. Two papers known to the authors explored the 
policy relevance of this topic, and one paper reported poverty 
reduction in a retrospective study conducted among households 
receiving palliative care in rural India.
Added value of this study
Levels of catastrophic expenditure are high after a diagnosis of 
advanced cancer in Malawi. Observed differences in total 
household expenditure and catastrophic costs for households 
receiving palliative care did not reach statistical significance due 
to limited access to palliative care in the study population.
Implications of all the available evidence
Palliative care might contribute to poverty reduction at 
household level in LMIC through reducing additional burdens of 
household expenditure on health care in the context of 
advanced disease. Larger studies with improved access to 
palliative care are needed to determine whether catastrophic 
household expenditure is reduced through receipt of palliative 
care, in the context of cancer or other advanced conditions.
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School of Tropical Medicine Research Ethics Committee. 
The study protocol has been published elsewhere.16
Participants
Participant households (patient–carer dyads) were 
recruited sequentially from specialist clinics at the 
hospital when a patient was identified with a new 
diagnosis of advanced cancer (any one of Kaposi’s 
sarcoma, cervical cancer, oesophageal cancer, or hepato-
cellular carcinoma; appendix p 4). Patients were invited 
to take part in the study if 18 years or older, living less 
than 50 km from the hospital, with stable comorbidities 
(ie, temperature <37·4°C, blood pressure ≤140/90 mm Hg, 
WHO performance score ≤2), and an estimated 
prognosis of at least 3 months as determined by an 
experienced palliative care clinician. Following study 
enrolment, patients were asked to identify an unpaid 
family caregiver from the same household. Health-care 
use and related household costs, including sale of assets 
and loans taken out (dissaving), were recorded. HRQoL 
was recorded using the Chichewa version of the EuroQoL 
EQ-5D-3L tool.17 All costs for health care for cancer-
related illness were collated between diagnosis and 
6 months after diagnosis using the Patient and Carer 
Cancer Cost Survey.18 Repeat visits at 1 month and 
3 months were made at a site of preference chosen by the 
respondent (ie, home, nearby health centre, or hospital). 
The frequency of visits was designed to reduce recall 
time to improve the accuracy of self-reported costs.19 If a 
follow-up appointment was missed, patients were asked 
in the subsequent interviews about all costs and dissaving 
since their last attended appointment. We recorded 
receipt of palliative care as a binary exposure (yes/no) by 
household self-report and verified by manual checking of 
clinical records and hospital data management reports.
Households were defined as rural if they were located 
outside Blantyre urban administrative boundaries. 
Self-reported poverty levels were assessed based on 
World Bank definitions.20 In addition, households 
reported asset ownership and were divided into poverty 
tertiles derived from scores calculated from a locally 
developed proxy means test for poverty (appendix 
pp 11–13). Tertiles were used due to the relatively small 
sample size.
Statistical analysis
Comparing single variables (a response variable was 
the total household costs of health care from 
diagnosis to 6 months as a proportion of household 
income, predictor was the receipt of palliative care) a 
sample size of 55 households was required to detect a 
medium effect size at 6 months (as determined by 
Cohen’s f²=0·15). All power analyses were based on 
α=0·05; power=0·8, using two-sided tests. Accounting 
for an estimated 50% exclusions and 20% dropout, the 
cohort needed a sample size of 138 households. The 
study sample was partly based on feasibility, with an 
estimated 225 patients available for recruitment over a 
6 month period.
Analysis was completed using StataCorp version 15, 
R version 4.1.0 and Microsoft Excel (Windows 10). 
STROBE and CHEERS guidelines were used for 
reporting.
Procedures and outcomes
Only households reporting data for the primary outcome 
(total household costs on health care from diagnosis to 
6 months after diagnosis) were included in the descriptive 
analysis. Continuous variables were summarised as 
means (with 95% CI), and medians (with IQR) if data 
were skewed. Frequency tables and percentages were 
used for categorical variables. Wilcoxon rank sum test 
and Spearman correlation were used for comparisons. 
Fisher’s exact test and relative risk calculations were used 
to explore catastrophic costs on health care, comparing 
households that received palliative care with those that 
did not.
We formulated multiple linear regression models 
to investigate associations between palliative care 
receipt and total household costs on health over the 
6 months following diagnosis, expressed as a proportion 
of household income. We derived annual household 
income from monthly household income before the 
onset of symptoms. Total household costs included 
all direct medical and non-medical out-of-pocket 
expenditure, as well as indirect costs through lost 
productivity time for both patients and carers. Models 
were constructed based on previous literature, and 
controlled for socioeconomic status, health seeking 
behaviour, health status of patient at diagnosis, and 
cancer type (appendix pp 2–3).
Dissaving was defined as the sale of assets (eg, bicycles 
or land) or the acquisition of loans. Dissaving is regarded 
as a coping strategy to access health services in 
low-income settings.21 It might be more accurately 
recalled by household members than precise retro-
spective details of health-care related out-of-pocket 
expenditure and has been considered as a potential proxy 
marker of catastrophic costs.22 Households were deemed 
to have faced catastrophic costs on health care if their 
total costs were greater or equal to 20% of their annual 
income before illness onset.23 Catastrophic costs were 
described as relative risks by category, comparing those 
who received palliative care with those who did not.
Median EuroQoL EQ-5D-3L utility scores (Zimbabwe 
tariff) and visual analogue scale (VAS) scores were 
recorded at each timepoint. The two-sample Wilcoxon 
rank test was used for HRQoL comparisons between 
those who had received palliative care and those who 
had not, and Spearman correlation tests were used to 
investigate the relationship between VAS scores and 
utility scores. The unadjusted hazard of death was 
estimated using the Kaplan-Meier survival estimator, 
with survival disaggregated by poverty status, receipt of 
See Online for appendix
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palliative care, and cancer type (appendix pp 7–9). No 
multiple testing corrections were applied.
After their final study visit, as per local ethical 
requirements at the time of the study, households 
received local currency equivalent of US$10 
compensation per visit. Data were entered anonymously 
on Open Data Kit software using locked hand-held 
devices for data collection. These were stored in a locked 
room when not in use. Data were uploaded at the end of 
each working day onto a password-protected laptop and 
uploaded onto a secure server at the Malawi Liverpool 
Wellcome Trust Clinical Research Programme (Blantyre, 
Malawi). Data were erased once uploaded to a secondary 
server. The database was backed up on a locked and 
encrypted hard drive.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between Jan 16 and July 31, 2019, 156 households, 
comprising 280 individuals (156 patients and 
124 caregivers), in which a patient had been newly 
diagnosed with cancer were assessed for eligibility, of 
whom 150 households comprising 271 individuals 
(150 patients and 121 caregivers) were recruited (table 1). 
At 6 months, 89 (59%) households representing 
153 individuals (89 patients and 64 care givers) were 
available for analysis, 19 (21%) had received palliative 
care and 70 (79%) had not. Between diagnosis and 
6 months, 55 (37%) of 150 patients had died, with 
22 (40%) of these deaths having occurred before first 
follow-up at 1 month (appendix p 6). Median time from 
recruitment to death was 53 days (appendix pp 7–9). 
A total of five (3%) of 150 households missed 
one interview (two at 1 month and three at 3 months) 
but returned for the following interview. Six (4%) of 
150 households were lost to follow-up (figure, 
appendix p 6).
Median annual household income before illness 
onset was $204 (IQR 84–660), 60 (67%) of 89 households 
were living in extreme poverty (≤$1·90 per day). 
48 (54%) of 89 households were rural. The median age 
of patients was 50 years (IQR 40–57), and for caregivers 
was 40 years (32–49). 70 (79%) patients and 47 (73%) 
caregivers were female. Of the 89 patients, 60 (67%) 
had cervical cancer, 19 (21%) had oesophageal cancer, 
eight (9%) had Kaposi’s sarcoma, and two (2%) had 
hepatocellular carcinoma (table 1).
Median annual household income before illness onset 
for those who received palliative care was $537 
(IQR 107–821) and for those who did not receive palliative 
care was $179 (82–537; p=0·135). In the 6 months after 
diagnosis, median total household costs on health 
were $50 (IQR 11–101) for those who received palliative 
care and $55 (28–91) for those who did not (p=0·704; 
table 2). Median direct costs were $6 (IQR 4–26) for those 
receiving palliative care and $12 (0–21) for those who did 
not receive palliative care (p=0·252); median indirect 
costs were $36 (IQR 5–56) versus $33 (13–56; p=0·980).
Expressed as a proportion of household income, total 
household cost on health for those who received palliative 
care was 0·086 (IQR 0·037–0·579) compared with 0·278 
(0·085–0·692) for those who did not receive palliative 
care (p=0·126). After adjustment for other relevant 
variables through multiple linear regression analysis, the 
mean difference in total household costs on cancer 
related health care as a proportion of household income 
was –36% (95% CI –94 to 594) for those who received 
palliative care compared with those who did not receive 
palliative care (p=0·707; table 3). Two sensitivity analyses 
were done, over a shorter 3 month period following 
diagnosis, and using a different method of calculating 
the indirect costs. At 3 months, mean difference in total 
household costs on health care were –54% (95% CI 
–95 to 351, p=0·533) with receipt of palliative care. Using 







Rural 42 (60%) 6 (32%)
Urban 28 (40%) 13 (68%)
Most poor 23 (33%) 6 (32%)
Poor 23 (33%) 5 (26%)
Least poor 24 (34%) 8 (42%)
Living in extreme poverty 51 (73%) 9 (47%)
Patient
Female 56 (80%) 14 (74%)
Male 14 (20%) 5 (26%)
18–40 years 16 (23%) 4 (21%)
41–60 years 36 (51%) 11 (58%)
>60 years 18 (26%) 4 (21%)
Cervical cancer 50 (71%) 10 (53%)
Oesophageal cancer 16 (23%) 3 (16%)
Kaposi’s sarcoma 3 (4%) 5 (26%)
Liver cancer 1 (1%) 1 (5%)
Married 44 (63%) 8 (42%)
Single or divorced 7 (10%) 7 (37%)
Widowed 19 (27%) 4 (21%)
Carer
Female 34/49 (69%) 13/15 (87%)
Male 15/49 (31%) 2/15 (13%)
18–40 years 26/49 (53%) 6/15 (40%)
41–59 years 17/49 (35%) 8/15 (53%)
60–89 years 6/49 (12%) 1/15 (7%)
Data are n/N (%), unless otherwise stated.
Table 1: Household, patient, and carer demographics at 6 months 
following a diagnosis of advanced cancer, by receipt of palliative care
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minimum wage for calculating indirect costs at 6 months 
this difference was –46% (95% CI –95 to 490, p=0·608; 
table 3; appendix p 5).
57 (64%) of 89 households experienced catastrophic costs 
(table 4). Nine (47%) of 19 households who received 
palliative care experienced catastrophic costs compared 
with 48 (69%) of 70 who did not receive palliative care 
(relative risk 0·69, 95% CI 0·36–1·04, p=0·109). Catas-
trophic costs were more commonly experienced by rural 
households (37 [77%] of 48) than by urban households 
(20 [49%] of 41; p=0·008). Median dissaving at 6 months 
was $11 (IQR 0–30) for those receiving palliative care and 
$34 (14–75) for those who did not (p=0·005).
Health-related quality-of-life scores expressed in mean 
utility scores at diagnosis were 0·668 (95% CI 0·628–0·707) 
for patients and 0·826 (0·799–0·853) for carers, and 
6 months after diagnosis were 0·590 (0·534–0·646) for 
patients and 0·831 (0·799–0·863) for carers. Mean VAS 
scores were 39 (95% CI 35–42) for patients and 32 (29–35) 
for carers at diagnosis and 23 (20–25) for patients and 
18 (15–22) for carers (appendix p 10). Comparison of utility 
and VAS scores 6 months after diagnosis showed no 
difference between people who received palliative care 
versus those who did not in patients (mean utility scores of 
0·537 [95% CI 0·412–0·662] vs 0·606 [0·543–0·670], 
p=0·150; VAS scores of 23 [18–28] vs 22 [20–25], p=0·616) 
or caregivers (mean utility scores of 0·842 [0·768–0·917] 
vs 0·828 [0·792–0·864], p=0·647, VAS scores of 22 [6–38] 
vs 17 [15–19], p=0·284; table 5; appendix p 10). Patient 
HRQoL utility scores were negatively correlated with VAS 
scores at 6 months (data not presented). There was no 
correlation between total costs on health care at 6 months 
and HRQoL, irrespective of receipt of palliative care (data 
not presented).
Discussion 
Advanced cancer diagnosis is associated with catastrophic 
costs of health care and is a source of household poverty 
Figure: Trial profile
*19 households received palliative care, and 70 households did not receive 
palliative care.
6 households (6 patients) excluded
2 did not meet inclusion criteria
4 declined to participate
150 households eligible and included in study
(150 patients, 121 caregivers)
156 households (156 patients) assessed for eligibility
27 households (27 patients) excluded 
5 households lost to follow-up
22 patients died at or before 1 month
follow-up
123 total households
121 completed 1 month of follow-up (121 patients,
95 caregivers)
2 did not complete an interview but returned at
next follow-up
18 households (18 patients) excluded
     1 household lost to follow-up




102 completed 3 month follow-up  (102 patients,
74 caregivers)
3 did not complete an interview but returned at
next follow-up 
16 households (16 patients)




89 households completed 6 month follow-up
(89 patients, 64 caregivers)*




Household costs on health $55 (28–91) $50 (11–101)
Household income before illness $179 (82–537) $537 (107–821)






Dissaving at 6 months $34 (14–75) $11 (0–30)
Data are median US$,2019, (IQR), unless otherwise specified.
Table 2: Household income, health-related costs at 6 months, and 








–62·7% (–97·0 to 309·0) –36·1% (–94·1 to 594·0)
Urban –4·6% (–86·0 to 655·0) 155·0% (–65·1 to 1770·0)
Most poor 103·0% (–75·0 to 1550·0) ··†
Poor –22·7% (–91·0 to 544·0) ··†











Married 18·6% (–84·0 to 775·0) –16·7% (–89·7 to 575·0)
*Coefficients have been back transformed from the log–linear regressions and so 
can be interpreted as the % change in the health share of income with a one-unit 
change in the independent variable. †No data where the explanatory variable was 
not included in the regression model.
Table 3: Unadjusted and adjusted percentage difference in total 
household costs of health care as a proportion of household income 
following a diagnosis of advanced cancer, by receipt of palliative care
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in Malawi. Palliative care might reduce household costs 
on cancer related illness while maintaining quality of life. 
Reductions in dissaving were associated with receipt of 
palliative care in general. This might partly be explained 
by the higher median income of households receiving 
palliative care, although this suggestion requires further 
investigation. After controlling for socioeconomic, demo-
graphic, and disease related variables, we did not find a 
significant association between receipt of palliative care 
and household costs on health care related to advanced 
cancer at 6 months. Yet, the observed median difference 
in household costs was in the hypothesised direction and 
a similar pattern was observed in the sensitivity analyses. 
To our knowledge, this is the first time data have been 
gathered and analysed for households affected by 
advanced cancer in a low-income country setting.
One in five households affected by advanced cancer 
under routine care received palliative care, which 
contributed to the study having limited power to measure 
a significant difference. In a post-hoc calculation, we 
recalculated a minimum sample size of 500 households 
would be required to provide at least 80% power to detect 
a medium difference (Cohen’s d=0·5) between groups. 
Absolute amounts of dissaving were small across all 
households. Patients from 59% of households were 
alive 6 months after a diagnosis of advanced cancer, 
highlighting the importance of palliative care provision 
well before the last stages (hours and days) of life to 
mitigate longer periods of serious health-related 
suffering.
A key goal of universal health coverage is for 
individuals and communities to receive the health 
services they need without suffering financial hardship. 
This aim encompasses the full spectrum of health 
services, from health promotion to prevention, treat-
ment, rehabilitation, and palliative care.24 Data were 
deliberately gathered from patient–carer dyads in this 
study, recognising that financial hardship (and any 
potential cost savings) relating to serious illness is 
experienced beyond the individual, and, for a household, 
even beyond the death of the patient. 67% of households 
analysed in this study were living in extreme 
poverty before onset of symptoms. This finding is not 
surprising, reflecting the fact that 71% of the population 
of Malawi live in extreme poverty.25 This background 
provides context for the burden of catastrophic costs on 
health care related to cancer, which contributes further 
to household vulnerability. The World Bank, UN, and 
WHO have ambitious targets to reduce extreme poverty, 
recognising the role catastrophic costs play, stating that 
no one should be left behind.
There are some limitations to the concept of 
catastrophic costs, particularly in extremely poor house-
holds. Among them, many people who are sick forgo 
treatment rather than have catastrophic costs. This 
situation is missed in most studies and debates about 
universal health coverage.26 Additional qualitative work 
could address questions of whether and how receipt of 
palliative care influences household costs on health. We 
were unable to do further subgroup analysis because of 
the small number of households receiving palliative care. 
Some details of the timing, number, and type of contacts 
with palliative care services were available from clinical 
records; however, more detailed descriptors of support 
activities would help to describe receipt of palliative care 
as a continuous variable, which would have contributed 
to a more robust level of quantitative analyses on 
exposure.
The Global Atlas of Palliative Care states that only 12% of 
the 57 million adults and children who need palliative care, 
to reduce serious health-related suffering, currently receive 
it.27 Before starting the study, we considered that it was 
unethical to randomly assign households to palliative care, 
opting to use an observational study design conducted 
within a routine care setting. All recruited households 
were affected by advanced cancer and fulfilled criteria to 
receive palliative care at diagnosis. Although services were 
offered free of charge within a government funded 
institution, crucial gaps in access to care were noted. 





Risk ratio (95% CI)
Household
All 48/70 (69%) 9/19 (47%) 0·69 (0·36–1·04)*
Rural 35/42 (83%) 2/6 (33%) 0·40 (0·00–0·88)†
Most poor 17/23 (74%) 2/6 (33%) 0·45 (0·00–1·05)†
Poor 14/23 (61%) 3/5 (60%) 0·99 (0·29–1·92)†
Least poor 17/24 (71%) 4/8 (50%) 0·71 (0·19–1·29)†
Extreme poverty 41/51 (80%) 7/9 (78%) 0·97 (0·60–1·141)†
Patient
Male 8/14 (57%) 1/5 (20%) 0·35 (0·06–2·14)†
Female 40/56 (71%) 8/14 (57%) 0·80 (0·49–1·29)†
Kaposi’s sarcoma 2/3 (66%) 0/5 (0%) 0·00 (NA)
Cervical cancer 38/50 (76%) 7/10 (70%) 0·92 (0·51–1·342)†
Oesophageal cancer 8/16 (50%) 1/3 (33%) 0·67 (0·00–2·13)†
Hepatocellular 
carcinoma
0/1 (0%) 1/1 (100%) NA (NA)
Other
Less than median 
household income 
before illness
33/37 (89%) 6/7 (86%) 0·96 (0·62–1·23)†
Greater than median 
total household costs 
on health
32/36 (89%) 6/8 (75%) 0·84 (0·45–1·17)†
Data are n/N (%), unless otherwise stated. NA=not available. *Confidence 
interval obtained using a small–sample–adjusted unrestricted maximum 
likelihood estimator and the Wald normal approximation. †Confidence interval 
obtained by using the percentile method and bootstrapping (drawing repeated 
binomial samples for each group with the empirical probability of experiencing 
catastrophic costs). 
Table 4: Catastrophic health-related costs (20% threshold of household 
income) following a diagnosis of advanced cancer, by receipt of 
palliative care (n=89)
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operating radius were more likely to access services 
(table 1). Where integrated outpatient services existed that 
supported referral to palliative care (eg, the dedicated 
weekly palliative care Kaposi’s sarcoma outpatient clinic), 
patients were more likely to receive care. Recom-
mendations from WHO and the Lancet Commission for 
integrated models of palliative care early in the cancer care 
pathway require urgent implementation.28,29
We also noted the lower receipt of palliative care among 
people who live in extreme poverty in rural areas, which 
is where most Malawians live. Integration of services at 
all levels with effective linkages between hospital and 
community-based care would reduce the substantial 
transport costs for households. Studies detailing costs 
and outcomes associated with established and innovative 
models of care—eg, mobile outreach, mentorship, and 
support of staff in rural health facilities and mHealth30 
might be appropriate.
It is striking that HRQoL utility scores were not 
negatively related to levels of total household costs on 
health care. The main purpose of recording HRQoL was 
to comment on whether any cost savings attributed to 
palliative care were gained at the expense of quality of 
life—ie, whether households were preventing increased 
spending on health-related costs simply by stopping any 
form of health care. The finding that there were no 
significant differences in HRQoL metrics (utility scores 
and VAS scores) between people who received palliative 
care and those who did not broadly suggests that cost 
savings were not gained at the expense of HRQoL.
Utility scores were higher than those observed in an 
earlier study among inpatients at the same institution.31 
Observed reductions in HRQoL over time were not 
unexpected, given that patients had advanced (and 
advancing) cancer. This study was not designed or 
powered to explore differences in quality-of-life relating to 
receipt of palliative care. The relevance and sensitivity of 
the EuroQoL EQ-5D to adequately capture changes 
in HRQoL in populations with advanced disease is 
contested.32 Higher utility scores should be reflected by 
higher VAS scores; our finding of negative correlation 
between utility scores and VAS scores for patients at 
6 months provides some indication of difficulties in using 
this tool and warrants further exploration. No validation 
of existing HRQoL measures for populations with 
palliative care needs in low-income and middle-income 
countries presents difficulties, particularly as reporting of 
quality-adjusted life-years, disability-adjusted life-years, 
and incremental cost-effectiveness ratios determine 
priorities for national Essential Health Packages.33
Our study has strengths and limitations due to its 
purposely modest, single-centre observational design. 
Although public health services in Malawi are provided 
free at the point of care, financed by taxation and donor 
funding, there are limited facilities for cancer care, for 
example, no radiotherapy. Health financing environ-
ments and stage of development of oncology and 
palliative care services vary considerably within and 
by region, affecting generalisability of findings. Self-
reported cost data might be subject to recall bias, despite 
short recall periods. Seasonal variations affect income in 
Malawi’s largely rural, subsistence farming economy 
and could confound findings. Refusal (6%) and loss to 
follow-up (4%) rates were low and potential selection 
bias due to loss to follow-up was limited. Loss through 
death of patients was high, as expected, and these 
households were largely excluded in the data collection 
and analyses. Potential systematic errors resulting from 
study recruitment patterns (clinically stable, majority 
female outpatients) and through referral patterns to 
palliative care must be noted. Our analyses do not reflect 
costs or HRQoL experiences of patients who were less 
stable at diagnosis.
This prospective descriptive study provides essential 
data to explore the impact of receipt of palliative care on 
household costs of health care following a diagnosis of 
advanced cancer in a low-income country setting. Larger 
studies should be conducted across various settings 
using the tools and concepts outlined in this Article. 
However, sample size requirements would be reduced 
where access to palliative care is improved. Future work 
should explore barriers to, and successes in, models of 
early integration of palliative care for patients with 
advanced cancer, defining and describing the intervention 
exposure (palliative care) in more detail. Ways to 
comprehensively report cost data in households where 
patients die should be described. Unfortunately, paucity 
of funding for both hospital and community services and 
related research will hamper the development of the 
evidence base. As cancer research advances in low-
income and middle-income countries, there is a crucial 
need for improved operational tools to gather socio-
economic outcomes alongside disease related outcomes 
in recognition of the high levels of catastrophic costs 
described in this and other studies. Resource-stratified, 
evidence-based global guidelines have been published 
for palliative care.34 Based on our findings, these previous 
calls for new and integrated models of care for non-
communicable diseases and other chronic conditions 
under universal health coverage should also consider 
including access to publicly funded palliative care.
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